Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Decrease in Short Interest

Keros Therapeutics, Inc. (NASDAQ:KROS) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,494,814 shares, a decline of 24.9% from the March 15th total of 1,989,399 shares. Based on an average daily trading volume, of 568,956 shares, the days-to-cover ratio is currently 2.6 days. Currently, 9.5% of the company’s shares are sold short.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the last quarter. Invesco Ltd. grew its position in shares of Keros Therapeutics by 16.6% during the fourth quarter. Invesco Ltd. now owns 87,428 shares of the company’s stock worth $1,780,000 after acquiring an additional 12,449 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Keros Therapeutics during the fourth quarter worth about $1,223,000. XTX Topco Ltd bought a new position in Keros Therapeutics in the 4th quarter valued at about $212,000. Finally, VARCOV Co. bought a new position in Keros Therapeutics in the 4th quarter valued at about $261,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Up 1.4%

KROS stock traded up $0.16 during trading on Wednesday, hitting $11.71. 305,226 shares of the company’s stock traded hands, compared to its average volume of 416,665. Keros Therapeutics has a 52 week low of $10.41 and a 52 week high of $22.55. The stock has a fifty day moving average price of $13.34 and a two-hundred day moving average price of $16.28. The stock has a market capitalization of $230.92 million, a price-to-earnings ratio of 6.43 and a beta of 0.98.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $3.66 million. Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The firm’s revenue for the quarter was down 87.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.14) EPS. As a group, equities research analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on KROS shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, March 5th. Zacks Research cut shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. TD Cowen raised shares of Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Finally, Wall Street Zen cut shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Hold” and a consensus price target of $21.33.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.